Unveiling CYP-induced side effects including hemorrhagic cystitis influenced clinical and basic research communities to dedicate significant efforts to establish a therapeutic strategy to prevent CYP/acrolein-induced cystitis whilst maintaining the benefits of CYP. This evidence concerns the gene PPIG and cystitis.